Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00. Following the sale, the insider directly owned 126,019 shares in the company, valued at $40,418,073.87. This trade represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Solomon Moshkevich also recently made the following trade(s):
- On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The shares were sold at an average price of $326.89, for a total transaction of $4,955,652.40.
- On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
- On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total value of $305,900.28.
- On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total value of $263,094.90.
- On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total value of $818,700.00.
Natera Trading Up 0.8%
Shares of NTRA stock opened at $327.67 on Friday. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18. The business’s 50 day moving average is $291.29 and its two-hundred day moving average is $237.00. The company has a market capitalization of $47.23 billion, a P/E ratio of -240.93 and a beta of 1.54.
Wall Street Analysts Forecast Growth
NTRA has been the subject of a number of research reports. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Robert W. Baird set a $348.00 price objective on Natera in a research note on Friday, August 7th. UBS Group set a $260.00 target price on Natera in a report on Wednesday, June 24th. JPMorgan Chase & Co. lifted their price target on Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Piper Sandler increased their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $319.38.
Get Our Latest Stock Report on NTRA
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Trust Co. of Vermont purchased a new position in Natera during the second quarter worth about $26,000. Reflection Asset Management purchased a new stake in shares of Natera in the 4th quarter valued at approximately $29,000. Elevation Wealth Partners LLC purchased a new stake in shares of Natera in the 2nd quarter valued at approximately $30,000. Palladiem LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $31,000. Finally, Horizon Investments LLC acquired a new stake in shares of Natera during the 3rd quarter worth approximately $32,000. Institutional investors and hedge funds own 99.90% of the company’s stock.
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Recommended Stories
- Five stocks we like better than Natera
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
